[redacted]

(THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)

C

Sample Name	CEFOPERAZONE INJECTION-IP.1.0gm.	**Mfg Lic No**	[redacted]
Submitted By	Quality Control Advisor. (MMDSL) Shillong.	**Report No**	
Address	DHS LaitumkhrahNHM,EastKhasi Hills Meghalaya.	**Receipt Date**	19-Mar-24
Mfg By	N.S.	**Report Date**	09-Apr-24
Supplied By	N.S.	**Ref No**	N.S.

Batch No	Mfg. Date	Exp Date	Batch Size	Sample Qty
MMDSL/QC-0113	09/2023	08/2025	N.S.	30 VIALS.

RESULT OF ANALYSIS

Date / Period of Performance of test 19/03/2024 to 09/04/2024.

Reference to protocol :- I.P-2022.

Description :- White powder filled in transparent glass vials.

Identification (A)(by HPLC) :- Complies.
(B) :- Complies.

Average fill :- 1.0563gm.
Uniformity of weight :- Within limit.
Clarity of solution (of Reconstituted solutin) :- Complies.

Bacterial endotoxins :- Less than 0.20EU/mg of Cefoperazone — Limit NMT- 0.20EU/mg. of Cefoperazone.

Sterility :- Complies with the test for sterility.

		LIMIT	
		Lower	Upper
pH (Determined in 25%w/v solution)	:- 5.42	4.5	6.5
Water(by KF)	:- 4.71%w/w		NMT-5.0 %w/w
Particulate matter (Of reconstituted solution)	:- Complies.		

Assay (by HPLC) :- Each vial contains:-

			LIMIT		
Contents of	Obtained	Claim	Lower	Upper	Method
Cefoperazone Sodium cal.as Anhy.Cefoperazone	:- 995.62mg	1000.0mg	900.0mg	1200mg	IP.

NOTE:- SAMPLE CONSUMED IN TESTING.

Report:In Opinion of the undersigned,The sample refe
as defined in the Act and the rules made there unde
per IP.

[redacted]

NOTE : 1. The result listed refer only to the tested samples and applicable parameter. Endorsement of products is neither inferred nor implied.
2. Sample not drawn by us. Total liability of this laboratory limited to the invoice amount.
3. This report is not be reproduced wholly or in part and cannot be used as an evidence in the Court of Law and should not be used in any advertising media without special permission in writing.